Enhanced Vancomycin Hemodialysis model now available in DoseMeRx!Learn more →

Clinical Evidence

Published studies and evidence support DoseMeRx achieving therapeutic doses of important medications to streamline operations, improve drug effectiveness, and reduce adverse events.

Peer-reviewed Literature​

DoseMeRx has demonstrated clear clinical and operational benefits in independent peer-reviewed studies. 

DoseMeRx increases the proportion of vancomycin patients achieving target AUC24 and the percentage in target therapeutic range
Authors: Luqman Vali, David R Jenkins, Rakesh Vaja, Hussain Mulla | Download Paper

DoseMeRx (Bayesian estimation) accurately identifies patients at risk of AKI from just one assay
Authors: Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. | Download Paper

Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
Authors: Hennig S, Holthouse F, Staatz CE. |Download Paper

Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.
Authors:  Burgard M, Sandaradura I, van Hal SJ, Stacey S, Hennig S.| Download Paper

Bayesian algorithms (such as those used in the models within DoseMeRx) enable sophisticated decision support that improves outcomes by customizing therapeutic drug doses for individual patients
Authors:  M Neely | Download Paper

Cyclosporine treatment for patients with autoimmune diseases shows improved therapeutic range and number of days in range by using DoseMeRx.
Authors:  Stopinšek, et. al | Download Paper

Poster Presentations

DoseMeRx and our customers are continuously working on scientific poster presentations that are presented at conferences around the country.

AUC24 vancomycin Bayesian-based Dosing: Increasing Therapeutic Target Attainment with Decreased TDM cost
In this study, we compare therapeutic range attainment across five hospitals using vancomycin trough-based dosing versus five hospitals using Bayesian-supported vancomycin AUC24 based dosing. Poster presented at: ID Week Annual Meeting; October 4, 2019; Washington, DC. Download Poster

DoseMeRx is the only HITRUST CSF certified Bayesian dosing platform.

By implementing HITRUST CSF requirements we have addressed every standard and implementation in the HIPAA Security Rule.

Demandez une démo

Découvrez à quel point DoseMeRx est facile à utiliser et à intégrer dans votre journée de travail.

Demandez une démo ci-dessous. Vous pouvez également nous appeler au +1 (832) 358-3308 ou nous envoyer un e-mail à hello@dosemehealth.com

HIPAA Privacy Statement | Privacy policy | DoseMe & the GDPR | Copyright © 2012 - 2024 DoseMe Pty Ltd. All Rights Reserved.
DoseMe® is a registered trademark of DoseMe Pty Ltd. DoseMeRx℠ and DoseMe℞℠ are service marks of DoseMe LLC.